Dosis
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Dosis firmographics
Firmographics- Name
- Dosis
- Website
- https://dosisinc.com
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Dosis industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Other Ambulatory Health Care Services (6219)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Medication Safety, Dosing & Drug Interaction CDS (HLACAGAB)
- akta.pro secondary industry
- Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH)
Keywords
Where Dosis is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Dosis business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Dosis product offering
Product offeringCore offering
Dosis sells an AI-powered personalized dosing platform intended for healthcare providers to determine individualized medication doses for patients. The platform replaces or augments standard dosing protocols with AI-driven, patient-specific dose recommendations as a clinical decision-support software tool.
Differentiator
Problem solved
Functional benefit
Products and services
- Dosis AI Personalized Dosing Platform An AI-powered software platform that provides personalized, patient-specific medication dose recommendations to healthcare providers, supporting clinical decision-making in drug dosing.
Companies that use Dosis
Customer profileIdeal customer profiles1 record
Dosis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Dosis partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Dosis competitors and assessment
Company assessmentEmerging players
- Arine: Arine applies AI to medication optimization and adherence for value-based care populations. It overlaps with Dosis on data-driven medication management but operates at the regimen/therapy level rather than per-dose decision support.
- Renalytix: Renalytix applies AI-driven diagnostics and prognostic tools to kidney disease, overlapping with Dosis on the CKD patient population and value-based nephrology contracting — though Renalytix focuses on risk prediction rather than dosing.
Others
- Health Catalyst: Health Catalyst is a healthcare data and analytics platform that increasingly embeds clinical improvement applications, including medication-related use cases. It is an adjacent data/analytics peer rather than a direct dosing competitor.
- First Databank (FDB): FDB supplies drug knowledge bases (including dosing and interaction data) that power EHRs and CDS systems worldwide. It is an ecosystem enabler and indirect competitor whose content underpins many dosing workflows Dosis targets.
- Wolters Kluwer (Medi-Span / UpToDate Lexidrug): Wolters Kluwer provides clinical drug information, including dosing guidance, integrated into provider workflows. It is an enabling/adjacent player whose dosing content competes for the same evidence-based decision moment.
Direct peers
- DoseMe: DoseMeRx (formerly DoseMe) provides Bayesian-model-based individualized dosing software for hospitals and pharmacists, targeting similar therapeutic areas (e.g., vancomycin, aminoglycosides). It directly competes with Dosis's personalized dosing proposition.
- InsightRX: InsightRX is a precision-dosing clinical decision support platform that uses Bayesian and ML models to individualize drug dosing for clinicians. It is the closest direct competitor to Dosis in AI-driven personalized dosing.
Broad incumbents
- Tabula Rasa HealthCare: Tabula Rasa (now part of ExactCare) combines proprietary pharmacogenomics and dosing science with pharmacy services to optimize medication regimens for at-risk patients. It is a broader, more established incumbent in medication safety and dosing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Dosis social profiles
Digital presenceDosis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dosis leadership team
Management profileNumber of profiles
Profiles3 records
Dosis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dosis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dosis
What does Dosis do?
Dosis sells an AI-powered personalized dosing platform intended for healthcare providers to determine individualized medication doses for patients. The platform replaces or augments standard dosing protocols with AI-driven, patient-specific dose recommendations as a clinical decision-support software tool.
When was Dosis founded?
Dosis was founded in 2017. It employs 1 to 10 people.
Where is Dosis based?
Dosis is headquartered in San Francisco, United States, in the North America region.
Who are Dosis's main competitors?
Emerging players on record are Arine and Renalytix. Others are Health Catalyst, First Databank (FDB) and Wolters Kluwer (Medi-Span / UpToDate Lexidrug). Direct peers are DoseMe and InsightRX. Tabula Rasa HealthCare is listed as a broad incumbent.
Does Dosis have an API?
No public API is recorded for Dosis.
What industry is Dosis in?
Dosis's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAB, Medication Safety, Dosing & Drug Interaction CDS, with a secondary code of HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools. Its NAICS code is 6219 and its SIC code is 8000.